Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05799287 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Telitacicept for IgA Nephropathy (TELIGAN)

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated December 16, 2025 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Oct 2025 to Jun 2026 Completion date: Dec 2025 to Jun 2026 · Eligibility criteria expanded, about 132 words · Study title shortened, about 3 wordsv5 Show 3 more changesShow less
    • Completion date: Dec 2025 to Jun 2026
    • Eligibility criteria expanded, about 132 words
    • Study title shortened, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Study sites revised (101)v4 See this version in full on ClinicalTrials.gov ↗
  3. Primary endpoints revised (2) Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 308 to confirmed 318 · Eligibility criteria expanded, about 20 words · 4 morev3 Show 7 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 308 to confirmed 318
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: 10 to 11
    • Site details revised at 101 of 101 sites
    • Study description expanded, about 1 word
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 80 to 101 · Start date changed from estimate of Apr 2023 to Apr 28, 2023v2 Show 2 more changesShow less
    • Study sites: 80 to 101
    • Start date changed from estimate of Apr 2023 to Apr 28, 2023
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the efficacy and safety of Telitacicept in patients with primary IgA nephropathy at risk of progressing to end-stage renal disease(ESRD), despite maximum tolerated treatment with renin-angiotensin system(RAS) blockade using angiotensin converting enzyme inhibitors (ACEIs) or angiotensin II type I receptor blockers (ARBs).
Trial Details
NCT Number NCT05799287
Lead Sponsor RemeGen Co., Ltd.
Conditions Primary IgA Nephropathy
Enrollment 318 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov